Which has stronger earnings & valuation, IDXX or SNN?

IDEXX Laboratories has higher earnings, but lower revenue than Smith & Nephew SNATS. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio IDEXX Laboratories $4.30B 9.53 $1.06B $14.22 36.62 Smith & Nephew SNATS $6.16B 1.80 $625M N/A N/A

Does the media favor IDXX or SNN?

In the previous week, IDEXX Laboratories and IDEXX Laboratories both had 3 articles in the media. IDEXX Laboratories' average media sentiment score of 0.00 beat Smith & Nephew SNATS's score of -0.01 indicating that IDEXX Laboratories is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment IDEXX Laboratories 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Smith & Nephew SNATS 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Which has higher valuation & earnings, DXCM or SNN?

DexCom has higher earnings, but lower revenue than Smith & Nephew SNATS. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio DexCom $4.66B 6.89 $836.30M $2.53 33.63 Smith & Nephew SNATS $6.16B 1.80 $625M N/A N/A

Does the media refer more to DXCM or SNN?

In the previous week, DexCom had 5 more articles in the media than Smith & Nephew SNATS. MarketBeat recorded 8 mentions for DexCom and 3 mentions for Smith & Nephew SNATS. DexCom's average media sentiment score of 0.44 beat Smith & Nephew SNATS's score of -0.01 indicating that DexCom is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment DexCom 3 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Smith & Nephew SNATS 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Which has better valuation & earnings, SNN or RMD?

ResMed has lower revenue, but higher earnings than Smith & Nephew SNATS. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Smith & Nephew SNATS $6.16B 1.80 $625M N/A N/A ResMed $5.65B 5.61 $1.52B $10.43 21.08

Does the media prefer SNN or RMD?

In the previous week, ResMed had 7 more articles in the media than Smith & Nephew SNATS. MarketBeat recorded 10 mentions for ResMed and 3 mentions for Smith & Nephew SNATS. ResMed's average media sentiment score of 0.81 beat Smith & Nephew SNATS's score of -0.01 indicating that ResMed is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Smith & Nephew SNATS 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral ResMed 4 Very Positive mention(s) 4 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher earnings and valuation, SNN or GEHC?

GE HealthCare Technologies has higher revenue and earnings than Smith & Nephew SNATS. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Smith & Nephew SNATS $6.16B 1.80 $625M N/A N/A GE HealthCare Technologies $20.63B 1.41 $2.08B $4.36 14.73

Does the media favor SNN or GEHC?

In the previous week, GE HealthCare Technologies had 3 more articles in the media than Smith & Nephew SNATS. MarketBeat recorded 6 mentions for GE HealthCare Technologies and 3 mentions for Smith & Nephew SNATS. GE HealthCare Technologies' average media sentiment score of 0.41 beat Smith & Nephew SNATS's score of -0.01 indicating that GE HealthCare Technologies is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Smith & Nephew SNATS 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral GE HealthCare Technologies 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate SNN or PHG?

Smith & Nephew SNATS currently has a consensus price target of $31.91, suggesting a potential upside of 21.03%. Given Smith & Nephew SNATS's higher possible upside, equities research analysts plainly believe Smith & Nephew SNATS is more favorable than Koninklijke Philips. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Smith & Nephew SNATS 1 Sell rating(s) 10 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Koninklijke Philips 0 Sell rating(s) 5 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has stronger valuation & earnings, SNN or PHG?

Koninklijke Philips has higher revenue and earnings than Smith & Nephew SNATS. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Smith & Nephew SNATS $6.16B 1.80 $625M N/A N/A Koninklijke Philips $20.17B 1.16 $1.01B $1.36 17.55

Does the media favor SNN or PHG?

In the previous week, Smith & Nephew SNATS had 1 more articles in the media than Koninklijke Philips. MarketBeat recorded 3 mentions for Smith & Nephew SNATS and 2 mentions for Koninklijke Philips. Smith & Nephew SNATS's average media sentiment score of -0.01 beat Koninklijke Philips' score of -0.52 indicating that Smith & Nephew SNATS is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Smith & Nephew SNATS 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Koninklijke Philips 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Negative

Smith & Nephew SNATS (SNN) Competitors

$26.45 -0.13 (-0.48%)

Closing price 03:59 PM Eastern

Extended Trading

$26.42 -0.03 (-0.10%)

As of 07:30 PM Eastern

Compare

SNN vs. IDXX, DXCM, RMD, GEHC, and PHG

Should you buy Smith & Nephew SNATS stock or one of its competitors? Smith & Nephew SNATS's main competitors and comparable companies include IDEXX Laboratories (IDXX), DexCom (DXCM), ResMed (RMD), GE HealthCare Technologies (GEHC), and Koninklijke Philips (PHG). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment" industry.

How does Smith & Nephew SNATS compare to IDEXX Laboratories?

IDEXX Laboratories (NASDAQ:IDXX) and Smith & Nephew SNATS (NYSE:SNN) are both large-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, dividends, media sentiment, analyst recommendations, profitability, institutional ownership and valuation.

IDEXX Laboratories has a net margin of 25.03% compared to Smith & Nephew SNATS's net margin of 0.00%. IDEXX Laboratories' return on equity of 71.96% beat Smith & Nephew SNATS's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
IDEXX Laboratories	25.03%	71.96%	33.60%
Smith & Nephew SNATS	N/A	N/A	N/A

IDEXX Laboratories presently has a consensus price target of $747.00, indicating a potential upside of 43.44%. Smith & Nephew SNATS has a consensus price target of $31.91, indicating a potential upside of 21.03%. Given IDEXX Laboratories' stronger consensus rating and higher possible upside, equities research analysts clearly believe IDEXX Laboratories is more favorable than Smith & Nephew SNATS.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
IDEXX Laboratories	0 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.60
Smith & Nephew SNATS	1 Sell rating(s)	10 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

IDEXX Laboratories has a beta of 1.55, suggesting that its stock price is 55% more volatile than the broader market. Comparatively, Smith & Nephew SNATS has a beta of 0.53, suggesting that its stock price is 47% less volatile than the broader market.

In the previous week, IDEXX Laboratories and IDEXX Laboratories both had 3 articles in the media. IDEXX Laboratories' average media sentiment score of 0.00 beat Smith & Nephew SNATS's score of -0.01 indicating that IDEXX Laboratories is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
IDEXX Laboratories	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Smith & Nephew SNATS	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

87.8% of IDEXX Laboratories shares are held by institutional investors. Comparatively, 25.6% of Smith & Nephew SNATS shares are held by institutional investors. 0.8% of IDEXX Laboratories shares are held by company insiders. Comparatively, 1.0% of Smith & Nephew SNATS shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

IDEXX Laboratories has higher earnings, but lower revenue than Smith & Nephew SNATS.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IDEXX Laboratories	$4.30B	9.53	$1.06B	$14.22	36.62
Smith & Nephew SNATS	$6.16B	1.80	$625M	N/A	N/A

Summary

IDEXX Laboratories beats Smith & Nephew SNATS on 11 of the 13 factors compared between the two stocks.

How does Smith & Nephew SNATS compare to DexCom?

DexCom (NASDAQ:DXCM) and Smith & Nephew SNATS (NYSE:SNN) are both large-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their risk, media sentiment, valuation, dividends, analyst recommendations, earnings, profitability and institutional ownership.

DexCom presently has a consensus target price of $89.74, indicating a potential upside of 5.46%. Smith & Nephew SNATS has a consensus target price of $31.91, indicating a potential upside of 21.03%. Given Smith & Nephew SNATS's higher possible upside, analysts clearly believe Smith & Nephew SNATS is more favorable than DexCom.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DexCom	1 Sell rating(s)	2 Hold rating(s)	19 Buy rating(s)	2 Strong Buy rating(s)	2.92
Smith & Nephew SNATS	1 Sell rating(s)	10 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

DexCom has higher earnings, but lower revenue than Smith & Nephew SNATS.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DexCom	$4.66B	6.89	$836.30M	$2.53	33.63
Smith & Nephew SNATS	$6.16B	1.80	$625M	N/A	N/A

97.8% of DexCom shares are held by institutional investors. Comparatively, 25.6% of Smith & Nephew SNATS shares are held by institutional investors. 0.3% of DexCom shares are held by insiders. Comparatively, 1.0% of Smith & Nephew SNATS shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

DexCom has a net margin of 20.12% compared to Smith & Nephew SNATS's net margin of 0.00%. DexCom's return on equity of 35.94% beat Smith & Nephew SNATS's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
DexCom	20.12%	35.94%	14.75%
Smith & Nephew SNATS	N/A	N/A	N/A

DexCom has a beta of 1.48, indicating that its share price is 48% more volatile than the broader market. Comparatively, Smith & Nephew SNATS has a beta of 0.53, indicating that its share price is 47% less volatile than the broader market.

In the previous week, DexCom had 5 more articles in the media than Smith & Nephew SNATS. MarketBeat recorded 8 mentions for DexCom and 3 mentions for Smith & Nephew SNATS. DexCom's average media sentiment score of 0.44 beat Smith & Nephew SNATS's score of -0.01 indicating that DexCom is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
DexCom	3 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Smith & Nephew SNATS	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Summary

DexCom beats Smith & Nephew SNATS on 12 of the 15 factors compared between the two stocks.

How does Smith & Nephew SNATS compare to ResMed?

Smith & Nephew SNATS (NYSE:SNN) and ResMed (NYSE:RMD) are both large-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their dividends, valuation, earnings, analyst recommendations, media sentiment, profitability, institutional ownership and risk.

25.6% of Smith & Nephew SNATS shares are owned by institutional investors. Comparatively, 55.0% of ResMed shares are owned by institutional investors. 1.0% of Smith & Nephew SNATS shares are owned by insiders. Comparatively, 0.7% of ResMed shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

ResMed has lower revenue, but higher earnings than Smith & Nephew SNATS.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Smith & Nephew SNATS	$6.16B	1.80	$625M	N/A	N/A
ResMed	$5.65B	5.61	$1.52B	$10.43	21.08

Smith & Nephew SNATS pays an annual dividend of $0.93 per share and has a dividend yield of 3.5%. ResMed pays an annual dividend of $2.64 per share and has a dividend yield of 1.2%. ResMed pays out 25.3% of its earnings in the form of a dividend. ResMed has increased its dividend for 13 consecutive years.

Smith & Nephew SNATS has a beta of 0.53, indicating that its share price is 47% less volatile than the broader market. Comparatively, ResMed has a beta of 0.75, indicating that its share price is 25% less volatile than the broader market.

Smith & Nephew SNATS currently has a consensus target price of $31.91, indicating a potential upside of 21.03%. ResMed has a consensus target price of $241.69, indicating a potential upside of 9.91%. Given Smith & Nephew SNATS's higher probable upside, analysts plainly believe Smith & Nephew SNATS is more favorable than ResMed.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Smith & Nephew SNATS	1 Sell rating(s)	10 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
ResMed	0 Sell rating(s)	9 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.44

ResMed has a net margin of 26.94% compared to Smith & Nephew SNATS's net margin of 0.00%. ResMed's return on equity of 25.58% beat Smith & Nephew SNATS's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Smith & Nephew SNATS	N/A	N/A	N/A
ResMed	26.94%	25.58%	18.89%

In the previous week, ResMed had 7 more articles in the media than Smith & Nephew SNATS. MarketBeat recorded 10 mentions for ResMed and 3 mentions for Smith & Nephew SNATS. ResMed's average media sentiment score of 0.81 beat Smith & Nephew SNATS's score of -0.01 indicating that ResMed is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Smith & Nephew SNATS	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
ResMed	4 Very Positive mention(s)	4 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

ResMed beats Smith & Nephew SNATS on 12 of the 17 factors compared between the two stocks.

How does Smith & Nephew SNATS compare to GE HealthCare Technologies?

Smith & Nephew SNATS (NYSE:SNN) and GE HealthCare Technologies (NASDAQ:GEHC) are both large-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, media sentiment, analyst recommendations, dividends, valuation, risk, institutional ownership and earnings.

Smith & Nephew SNATS pays an annual dividend of $0.93 per share and has a dividend yield of 3.5%. GE HealthCare Technologies pays an annual dividend of $0.14 per share and has a dividend yield of 0.2%. GE HealthCare Technologies pays out 3.2% of its earnings in the form of a dividend. GE HealthCare Technologies has increased its dividend for 1 consecutive years.

25.6% of Smith & Nephew SNATS shares are held by institutional investors. Comparatively, 82.1% of GE HealthCare Technologies shares are held by institutional investors. 1.0% of Smith & Nephew SNATS shares are held by insiders. Comparatively, 0.4% of GE HealthCare Technologies shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

GE HealthCare Technologies has higher revenue and earnings than Smith & Nephew SNATS.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Smith & Nephew SNATS	$6.16B	1.80	$625M	N/A	N/A
GE HealthCare Technologies	$20.63B	1.41	$2.08B	$4.36	14.73

Smith & Nephew SNATS currently has a consensus price target of $31.91, suggesting a potential upside of 21.03%. GE HealthCare Technologies has a consensus price target of $78.39, suggesting a potential upside of 22.10%. Given GE HealthCare Technologies' stronger consensus rating and higher probable upside, analysts plainly believe GE HealthCare Technologies is more favorable than Smith & Nephew SNATS.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Smith & Nephew SNATS	1 Sell rating(s)	10 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
GE HealthCare Technologies	0 Sell rating(s)	11 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.50

In the previous week, GE HealthCare Technologies had 3 more articles in the media than Smith & Nephew SNATS. MarketBeat recorded 6 mentions for GE HealthCare Technologies and 3 mentions for Smith & Nephew SNATS. GE HealthCare Technologies' average media sentiment score of 0.41 beat Smith & Nephew SNATS's score of -0.01 indicating that GE HealthCare Technologies is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Smith & Nephew SNATS	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
GE HealthCare Technologies	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Smith & Nephew SNATS has a beta of 0.53, meaning that its stock price is 47% less volatile than the broader market. Comparatively, GE HealthCare Technologies has a beta of 0.73, meaning that its stock price is 27% less volatile than the broader market.

GE HealthCare Technologies has a net margin of 9.33% compared to Smith & Nephew SNATS's net margin of 0.00%. GE HealthCare Technologies' return on equity of 20.12% beat Smith & Nephew SNATS's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Smith & Nephew SNATS	N/A	N/A	N/A
GE HealthCare Technologies	9.33%	20.12%	5.74%

Summary

GE HealthCare Technologies beats Smith & Nephew SNATS on 13 of the 17 factors compared between the two stocks.

How does Smith & Nephew SNATS compare to Koninklijke Philips?

Smith & Nephew SNATS (NYSE:SNN) and Koninklijke Philips (NYSE:PHG) are both large-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, institutional ownership, dividends, analyst recommendations, valuation, media sentiment, profitability and earnings.

Koninklijke Philips has a net margin of 6.30% compared to Smith & Nephew SNATS's net margin of 0.00%. Koninklijke Philips' return on equity of 14.38% beat Smith & Nephew SNATS's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Smith & Nephew SNATS	N/A	N/A	N/A
Koninklijke Philips	6.30%	14.38%	5.96%

Smith & Nephew SNATS currently has a consensus price target of $31.91, suggesting a potential upside of 21.03%. Given Smith & Nephew SNATS's higher possible upside, equities research analysts plainly believe Smith & Nephew SNATS is more favorable than Koninklijke Philips.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Smith & Nephew SNATS	1 Sell rating(s)	10 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Koninklijke Philips	0 Sell rating(s)	5 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

25.6% of Smith & Nephew SNATS shares are held by institutional investors. Comparatively, 13.7% of Koninklijke Philips shares are held by institutional investors. 1.0% of Smith & Nephew SNATS shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Koninklijke Philips has higher revenue and earnings than Smith & Nephew SNATS.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Smith & Nephew SNATS	$6.16B	1.80	$625M	N/A	N/A
Koninklijke Philips	$20.17B	1.16	$1.01B	$1.36	17.55

In the previous week, Smith & Nephew SNATS had 1 more articles in the media than Koninklijke Philips. MarketBeat recorded 3 mentions for Smith & Nephew SNATS and 2 mentions for Koninklijke Philips. Smith & Nephew SNATS's average media sentiment score of -0.01 beat Koninklijke Philips' score of -0.52 indicating that Smith & Nephew SNATS is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Smith & Nephew SNATS	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Koninklijke Philips	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Negative

Smith & Nephew SNATS pays an annual dividend of $0.93 per share and has a dividend yield of 3.5%. Koninklijke Philips pays an annual dividend of $0.84 per share and has a dividend yield of 3.5%. Koninklijke Philips pays out 61.8% of its earnings in the form of a dividend.

Smith & Nephew SNATS has a beta of 0.53, meaning that its share price is 47% less volatile than the broader market. Comparatively, Koninklijke Philips has a beta of 0.77, meaning that its share price is 23% less volatile than the broader market.

Summary

Smith & Nephew SNATS beats Koninklijke Philips on 9 of the 15 factors compared between the two stocks.

Get Smith & Nephew SNATS News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SNN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SNN vs. The Competition

Export

Metric	Smith & Nephew SNATS	Healthcare Equipment & Supplies Industry	Healthcare Sector	NYSE Exchange
Market Cap	$11.16B	$5.48B	$7.14B	$22.65B
Dividend Yield	3.51%	1.81%	2.54%	3.73%
P/E Ratio	N/A	24.55	273.67	27.75
Price / Sales	1.80	67.76	611.82	21.41
Price / Cash	7.75	32.43	77.60	38.88
Price / Book	2.12	5.68	10.92	4.64
Net Income	$625M	$152.11M	$3.50B	$1.08B
7 Day Performance	-1.75%	-2.01%	-2.11%	-1.06%
1 Month Performance	-7.75%	-5.42%	-6.34%	-5.03%
1 Year Performance	-27.45%	2.75%	8.81%	5.78%

Smith & Nephew SNATS Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SNN Smith & Nephew SNATS	3.5756 of 5 stars	$26.45 -0.5%	$31.91 +20.6%	-27.9%	$11.16B	$6.16B	N/A	16,988
IDXX IDEXX Laboratories	4.4347 of 5 stars	$534.25 +1.0%	$747.00 +39.8%	-16.5%	$42.05B	$4.30B	37.53	11,000
DXCM DexCom	3.6168 of 5 stars	$86.57 -0.1%	$89.08 +2.9%	+30.5%	$32.63B	$4.66B	34.18	11,100	Analyst Forecast Insider Trade
RMD ResMed	4.0957 of 5 stars	$222.39 +0.1%	$241.69 +8.7%	-18.3%	$32.08B	$5.65B	21.32	11,370	News Coverage
GEHC GE HealthCare Technologies	4.5262 of 5 stars	$66.22 -0.8%	$78.39 +18.4%	-15.3%	$29.88B	$20.63B	15.17	54,000

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:SNN) was last updated on 10/2/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Smith & Nephew SNATS (SNN) Competitors

SNN vs. IDXX, DXCM, RMD, GEHC, and PHG

How does Smith & Nephew SNATS compare to IDEXX Laboratories?

Summary

How does Smith & Nephew SNATS compare to DexCom?

Summary

How does Smith & Nephew SNATS compare to ResMed?

Summary

How does Smith & Nephew SNATS compare to GE HealthCare Technologies?

Summary

How does Smith & Nephew SNATS compare to Koninklijke Philips?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SNN vs. The Competition

Smith & Nephew SNATS Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Smith & Nephew SNATS (SNN) Competitors

SNN vs. IDXX, DXCM, RMD, GEHC, and PHG

How does Smith & Nephew SNATS compare to IDEXX Laboratories?

Is IDXX or SNN more profitable?

Do analysts prefer IDXX or SNN?

Which has more volatility and risk, IDXX or SNN?

Does the media favor IDXX or SNN?

Do institutionals & insiders have more ownership in IDXX or SNN?

Which has stronger earnings & valuation, IDXX or SNN?

Summary

How does Smith & Nephew SNATS compare to DexCom?

Do analysts prefer DXCM or SNN?

Which has higher valuation & earnings, DXCM or SNN?

Do institutionals and insiders have more ownership in DXCM or SNN?

Is DXCM or SNN more profitable?

Which has more volatility & risk, DXCM or SNN?

Does the media refer more to DXCM or SNN?

Summary

How does Smith & Nephew SNATS compare to ResMed?

Do institutionals and insiders hold more shares of SNN or RMD?

Which has better valuation & earnings, SNN or RMD?

Is SNN or RMD a better dividend stock?

Which has more volatility and risk, SNN or RMD?

Do analysts prefer SNN or RMD?

Is SNN or RMD more profitable?

Does the media prefer SNN or RMD?

Summary

How does Smith & Nephew SNATS compare to GE HealthCare Technologies?

Is SNN or GEHC a better dividend stock?

Do institutionals and insiders believe in SNN or GEHC?

Which has higher earnings and valuation, SNN or GEHC?

Do analysts recommend SNN or GEHC?

Does the media favor SNN or GEHC?

Which has more volatility and risk, SNN or GEHC?

Is SNN or GEHC more profitable?

Summary

How does Smith & Nephew SNATS compare to Koninklijke Philips?

Is SNN or PHG more profitable?

Do analysts rate SNN or PHG?

Do institutionals & insiders have more ownership in SNN or PHG?

Which has stronger valuation & earnings, SNN or PHG?

Does the media favor SNN or PHG?

Is SNN or PHG a better dividend stock?

Which has more volatility and risk, SNN or PHG?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SNN vs. The Competition

Smith & Nephew SNATS Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools